» Articles » PMID: 28881805

Down Regulation of Human Positive Coactivator 4 Suppress Tumorigenesis and Lung Metastasis of Osteosarcoma

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Sep 9
PMID 28881805
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma is a kind of primary malignant bone tumor with the highest incidence and an extraordinarily poor prognosis and early pulmonary metastasis formation as a frequent occurrence. Transcriptional positive coactivator 4 (PC4) has multiple functions in DNA replication, transcription, repair and chromatin organization, even in tumorigenesis. However, the precise function of PC4 in osteosarcoma is still unclear and controversial. In this paper we found PC4 was upregulated in patient-derived osteosarcoma tissues compared to normal. Moreover, higher expression of PC4 was correlated with poorer overall survival and advanced clinicopathological tumor staging. Down regulation of PC4 in the highly metastatic osteosarcoma cells reduced the malignant behaviors and . Analyzing the downstream genes affected obviously by shPC4 with RNA sequencing, we found knocking down PC4 will inhibit the propensity for lung metastasis through transcriptional suppression of MMPs pathways. Taken together, PC4 may be an attractive therapeutic strategy for osteosarcoma, especially in preventing lung metastasis formation.

Citing Articles

Pathogenic Roles of RNA-Binding Proteins in Sarcomas.

Hai Y, Kawachi A, He X, Yoshimi A Cancers (Basel). 2022; 14(15).

PMID: 35954475 PMC: 9367343. DOI: 10.3390/cancers14153812.


The Human Positive Cofactor 4 is a Promising Chemotherapeutic Target in Lung Adenocarcinoma.

Sun T, Zhang J, Fan X, Long T, Tao S, Kang P J Oncol. 2021; 2021:9958483.

PMID: 34899911 PMC: 8664520. DOI: 10.1155/2021/9958483.


High Expression of and Low Expression of are Associated with Metastasis and Recurrence of Osteosarcoma and Unfavorable Survival Outcomes of the Patients.

Zhang Y, Zhao H, Xu W, Jiang D, Huang L, Li L J Cancer. 2019; 10(9):2091-2101.

PMID: 31205570 PMC: 6548156. DOI: 10.7150/jca.28480.

References
1.
Enneking W, Spanier S, Goodman M . A system for the surgical staging of musculoskeletal sarcoma. 1980. Clin Orthop Relat Res. 2003; (415):4-18. DOI: 10.1097/01.blo.0000093891.12372.0f. View

2.
Luo Y, Liang F, Zhang Z . PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry. 2009; 48(8):1838-46. PMC: 2765538. DOI: 10.1021/bi8020789. View

3.
Kojima T, Wang X, Fujiwara K, Osaka S, Yoshida Y, Osaka E . Inhibition of human osteosarcoma cell migration and invasion by a gene silencer, pyrrole-imidazole polyamide, targeted at the human MMP9 NF-κB binding site. Biol Pharm Bull. 2014; 37(9):1460-5. DOI: 10.1248/bpb.b14-00147. View

4.
Mohseny A, Szuhai K, Romeo S, Buddingh E, Briaire-de Bruijn I, de Jong D . Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009; 219(3):294-305. DOI: 10.1002/path.2603. View

5.
Murthy S, Ryan A, Carter A . SP-1 regulation of MMP-9 expression requires Ser586 in the PEST domain. Biochem J. 2012; 445(2):229-36. PMC: 3663053. DOI: 10.1042/BJ20120053. View